LATEST REPORTS
Epileptic Seizures Treatment Market Size, Statistics, Growth Trend Analysis, and Forecast Report, 2022 - 2032
Epileptic Seizures Treatment Market is segmented By Type Outlook (Repetitive Seizures, Status Epilepticus, Convulsive Status Epilepticus, Non-convulsive Status Epilepticus, Others); By Therapeutic Outlook (Midazolam, Alprazolam, Diazepam, Lorazepam, Phenytoin, phenytoin, Others); By End-use Outlook (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Generation Outlook (First Generation, Second Generation, Third Generation); By Route of Administration Outlook (Oral/Buccal, Rectal, Nasal, Parenteral); By Regional Outlook (North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, Nordic Region, Rest of Europe), Asia Pacific (China, Japan, India, ASEAN, Rest of Asia Pacific), Latin America (Brazil, Mexico, Rest of Latin America), Middle East & Africa (GCC, South Africa, Rest of the Middle East & Africa)
Published Date : 12-02-2022
Read More
Direct-to-Consumer Laboratory Testing Market Size, Statistics, Growth Trend Analysis, and Forecast Report, 2022 – 2032
Direct-to-Consumer Laboratory Testing Market is segmented by Sample Type (Blood, Urine, Saliva, and Others); By Test Type (Genetic Testing, Disease Risk Assessment Testing, CBC, Diabetes Testing, TSH Testing, and Others); By End User (Hospitals, Clinics, Specialty Labs, and Diagnostic Centers) By Geography (North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, Nordic Region, Rest of Europe), Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific), Latin America (Brazil, Mexico, Rest of Latin America), Middle East & Africa (South Africa, Rest of the Middle East & Africa)
Published Date : 12-23-2022
Read More
GLP1 Agonist Drug Market Size, Statistics, Growth Trend Analysis and Forecast Report, 2026 – 2036
The GLP-1 agonist market is segmented by drug type into long-acting agonists (once-weekly subcutaneous and oral formats) and short-acting agonists (daily or twice-daily agents). By molecule, the market spans semaglutide, tirzepatide, dulaglutide, liraglutide, exenatide, albiglutide, and orforglipron as an emerging small-molecule oral entrant. By route of administration, subcutaneous injectable pens represent the dominant format, with oral formulations gaining commercial traction. By indication, the market addresses type 2 diabetes, obesity and weight management, cardiovascular risk reduction, MASH/NAFLD, chronic kidney disease, and other emerging indications. By end-user setting, distribution flows through hospital pharmacies, retail pharmacies, and online pharmacies. By distribution channel, the market is further divided across specialty pharmacies, direct-to-patient models, compounding pharmacies, and telehealth platforms.
Published Date : 06-03-2026
Read More CATEGORIES
- Healthcare
- Pharmaceuticals
- Chemicals-and-Materials
- Manufacturing-and-Construction
- Power-and-Energy
- Automotive-and-Transportation
- Telecom-and-IT
- Aerospace-and-Defens
- Food-and-Beverages
- Business-and-Finance
- Semiconductor
- Next-Gen-Technologies
- Machinery
- Animal-Nutrition-and-Wellness
- Electronic-Appliances
- Company-profiles
- Miscellaneous
20% Free Customization ON ALL PURCHASE
*Terms & Conditions Apply
